A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

NCT06693908 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Ulcerative Colitis

Interventions

DRUG: Vixarelimab

Sponsor

Genentech, Inc.